How Close Are MiRNAs from Clinical Practice? A Perspective on the Diagnostic and Therapeutic Market

Overview

Journal EJIFCC

Specialty Biochemistry

Date 2019 Jul 3

PMID 31263388

Citations 148

Authors

E Bonneau

B Neveu

E Kostantin

G J Tsongalis

V De Guire

Affiliations

Soon will be listed here.

Abstract

The discovery of miRNAs in the mid-90s has changed the dogma of gene expression regulation. Currently, miRNAs are the main theme of thousands of publications each year and their involvement in human diseases is everyday more deeply understood. With that being known, what are the actual clinical applications of miRNAs and how far are they truly from the patients? To address this question, we reviewed the miRNA diagnostic and therapeutic market. With many companies developing miRNA panels, the activity is high in the diagnostic area. Some products, notably for thyroid cancer (Interpace Diagnostic), are already available to clinician and covered by major insurance companies. In comparison, the therapeutic market, mainly driven by miRNA mimics and antagomiR products, is less advanced. Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs. All of the miRNA-based drugs are currently in clinical trials and none have yet reached the pharmaceutical breakthrough. However, acquisition of miRNA-based companies by major pharmas is sending a positive feedback on their potentials. With multiple initiatives on their way, the next years will definitely be determinant for the miRNA market that is still in his infancy.

Citing Articles

Identification of sex-biased and gonadal developmental miRNAs during critical windows of early gonadal differentiation in the Chinese giant salamander (Andrias davidianus).

Yang S, Wang X, Yang H, Yan F, Xu L, Jian Z BMC Genomics. 2025; 26(1):238.

PMID: 40075305 PMC: 11905707. DOI: 10.1186/s12864-025-11419-x.

Post-transcriptional regulation supports the homeostatic expression of mature RNA.

Su Z, Fang M, Smolnikov A, Vafaee F, Dinger M, Oates E Brief Bioinform. 2025; 26(1).

PMID: 39913622 PMC: 11801271. DOI: 10.1093/bib/bbaf027.

MicroRNA-155 as Biomarker and Its Diagnostic Value in Breast Cancer: A Systematic Review.

Yeo B, Lee W, Mahmud R, Tan G, Wahid M, Cheah Y World J Oncol. 2025; 16(1):1-15.

PMID: 39850528 PMC: 11750751. DOI: 10.14740/wjon1955.

Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

References

Calin G, Dumitru C, Shimizu M, Bichi R, Zupo S, Noch E . Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24):15524-9. PMC: 137750. DOI: 10.1073/pnas.242606799. View

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

Bernards R . [The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference]. Ned Tijdschr Geneeskd. 2007; 150(52):2849-53. View

Lawrie C, Gal S, Dunlop H, Pushkaran B, Liggins A, Pulford K . Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x. View

Greco F, Hainsworth J . Introduction: unknown primary cancer. Semin Oncol. 2009; 36(1):6-7. DOI: 10.1053/j.seminoncol.2008.10.007. View

Metias S, Lianidou E, Yousef G . MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol. 2009; 62(9):771-6. DOI: 10.1136/jcp.2009.064717. View

Service R . Chemistry Nobel. Honors to researchers who probed atomic structure of ribosomes. Science. 2009; 326(5951):346-7. DOI: 10.1126/science.326_346. View

Bowler F, Diaz-Mochon J, Swift M, Bradley M . DNA analysis by dynamic chemistry. Angew Chem Int Ed Engl. 2010; 49(10):1809-12. DOI: 10.1002/anie.200905699. View

10.

Tijsen A, Creemers E, Moerland P, De Windt L, van der Wal A, Kok W . MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010; 106(6):1035-9. DOI: 10.1161/CIRCRESAHA.110.218297. View

11.

Boran A, Iyengar R . Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010; 13(3):297-309. PMC: 3068535. View

12.

Kato M, Buitrago D, Moo T, Keutgen X, Hoda R, Ricci J . Predictive value of cytologic atypia in indeterminate thyroid fine-needle aspirate biopsies. Ann Surg Oncol. 2011; 18(10):2893-8. PMC: 3626080. DOI: 10.1245/s10434-011-1635-1. View

13.

Peer D, Lieberman J . Special delivery: targeted therapy with small RNAs. Gene Ther. 2011; 18(12):1127-33. DOI: 10.1038/gt.2011.56. View

14.

Burnett J, Rossi J . RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012; 19(1):60-71. PMC: 3269031. DOI: 10.1016/j.chembiol.2011.12.008. View

15.

Meiri E, Mueller W, Rosenwald S, Zepeniuk M, Klinke E, Bocker Edmonston T . A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012; 17(6):801-12. PMC: 3380879. DOI: 10.1634/theoncologist.2011-0466. View

16.

Bongiovanni M, Spitale A, Faquin W, Mazzucchelli L, Baloch Z . The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 2012; 56(4):333-9. DOI: 10.1159/000339959. View

17.

Sheinerman K, Tsivinsky V, Crawford F, Mullan M, Abdullah L, Umansky S . Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY). 2012; 4(9):590-605. PMC: 3492224. DOI: 10.18632/aging.100486. View

18.

Lindow M, Kauppinen S . Discovering the first microRNA-targeted drug. J Cell Biol. 2012; 199(3):407-12. PMC: 3483128. DOI: 10.1083/jcb.201208082. View

19.

Tetreault N, De Guire V . miRNAs: their discovery, biogenesis and mechanism of action. Clin Biochem. 2013; 46(10-11):842-5. DOI: 10.1016/j.clinbiochem.2013.02.009. View

20.

De Guire V, Robitaille R, Tetreault N, Guerin R, Menard C, Bambace N . Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem. 2013; 46(10-11):846-60. DOI: 10.1016/j.clinbiochem.2013.03.015. View